Replies to post #141663 on Biotech Values

[DewDiligence]

p.s. Copaxone had a 40.2% TRx share in the US market in 1Q12—highest of any MS drug—according to Teva’s CC today.

[genisi]

Yes, assuming no generics and no BG-12 launch mid upper bound should be met.